News summary

The Double-Edged Sword of Therapy-Induced Senescence in Cancer Treatment

Source: Fight Aging! • Published: 09 Nov 2026, 11:22

Summarized by Masters of Longevity from Fight Aging!.

Review finds therapy-induced senescence harms heart tissues and promotes inflammaging.

The Double-Edged Sword of Therapy-Induced Senescence in Cancer Treatment
Key Takeaways
  • Therapy-induced senescence is common after chemo and radiotherapy.
  • Accumulated senescent cells were reported to drive cardiovascular dysfunction.
  • Senolytic and senomorphic strategies have not established clinical benefit.
Read the full article at Fight Aging! ↗

Continue exploring

Recommended MoL Picks

MoL PickCreatine and Cancer: Why New Mouse Studies Point in Opposite DirectionsCreatine strengthened antitumour immune cells in one mouse study—and promoted metastasis through platelets in another. The apparent contradiction reveals why neither result is a supplement recommendation.MoL PickApoB: The cholesterol signal LDL can missIn longevity medicine, the useful biomarkers are not always the exotic ones. ApoB is a relatively simple blood test that can sharpen cardiovascular prevention when LDL-C looks reassuring but particle burden remains high.MoL PickSemaglutide Extended Lifespan in Mice. What Would Make It a Human Longevity Drug?A new animal study sharpens an important question: when do benefits in a particular disease become evidence for a longer, healthier life?